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Abstract
Despite the progress achieved in the 
development of new directions in the 
diagnosis and treatment of idiopathic 
pulmonary arterial hypertension, it remains 
one of the most severe and prognostically 
unfavorable diseases. The article presents a 
clinical case and an algorithm for diagnosis of 
this rare disease, in respect to the decision­
making in clinical practice. The present case 
underscores the need to consider a broad 
differential diagnosis for marked dyspnea in 
mature patients, especially when the intensity 
of dyspnea is out of proportion to the severity 
of underlying heart or lung diseases, or 
when symptoms fail to subside as expected 
in response to conventional therapy. Early 
diagnosis of idiopathic pulmonary arterial 
hypertension is vitally important for initiating 
modern therapy in order to improve the 
quality and duration of life in such patients.
Keywords: pulmonary hypertension; right 
ventricle failure; right heart catheterization; 
calcium channel blockers; modern targeted 
therapy.
Аннотация
Несмотря на прогресс, достигнутый в 
развитии новых направлений в диагно­
стике и лечении, идиопатическая лёгоч­
ная артериальная гипертензия остаётся 
одним из наиболее тяжелых и прогности­
чески неблагоприятных заболеваний. В 
статье представлен клинический случай 
и описан алгоритм диагностики этого ред­
кого заболевания соответственно про­
цессу принятия решений в клинической 
практике. В данном наблюдении подчер­
кивается необходимость широкого прове­
дения дифференциальной диагностики 
в случае выраженной одышки у возраст­
ных пациентов, особенно когда интенсив­
ность одышки непропорциональна тяже­
сти основного заболевания сердца или 
легких, и если обычная терапия не про­
являет ожидаемого эффекта. Ранняя ди­
агностика идиопатической легочной арте­
риальной гипертензии является жизненно 
важной для начала современной терапии 
с целью улучшения качества и продолжи­
тельности жизни таких пациентов.
Ключевые слова: легочная гипертен­
зия; недостаточность правого желудочка; 
катетеризация правых отделов сердца; 
блокаторы кальциевых каналов; совре­
менная целевая терапия.
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Introduction. The term “idiopathic 
pulmonary arterial hypertension” (IPAH) was 
used for the first time in 1951 by Dresdale. 
This clinical condition is characterized by the 
presence of pre-capillary PH, in the absence 
of other causes of pre-capillary PH such as PH 
due to lung diseases, chronic thromboembolic 
PH, or other rare diseases [1]. IPAH 
corresponds to sporadic disease; the lowest 
estimates of its prevalence are 5.9 cases/ 
million in the adult population. IPAH affects 
women two times more often than men. The 
mean age of diagnosis making is 35 years. 
The disease has no family history of PH or 
known triggering factor [2]. However, specific 
gene mutations have been identified in such 
patients, including the bone morphogenetic 
protein receptor 2 gene, the activin receptor­
like kinase type-1 gene and the endoglin gene 
[3, 4]. It is a severe chronic disease with an 
unfavorable prognosis. The symptoms of IPAH 
are caused by developing RV hypertrophy 
and failure. They are usually non-specific and 
include breathlessness, fatigue, weakness, 
angina, syncope, and abdominal distension. In 
advanced cases symptoms such as jugular vein 
distension, hepatomegaly, peripheral oedema, 
and ascites might occur [5, 6]. In untreated 
patients with IPAH or heritable PAH, historical 
data showed a median survival of 6 months 
for WHO-FC (World Health Organization -  
Functional Class) IV, 2.5 years for WHO-FC 
III, and 6 years for WHO-f C I and II. The most 
common causes of death are terminal right 
ventricle failure and cardiac arrest [7].
Case report. The case patient, a 47-year- 
old man checked into Kharkiv Regional 
Hospital with marked dyspnea during minimal 
physical activity (walking up to 70 m, climbing 
half flight of stairs), paroxysms of nocturnal 
dyspnea, tachycardia, chest pain, fatigue, 
and episodical increases of blood pressure. 
Symptoms were typically absent at rest.
The described above symptoms of disease 
are nonspecific and may correspond to multiple 
clinical conditions, capable of provoking
significant dyspnea, including heart diseases 
(systolic dysfunction, diastolic dysfunction, 
and valvular disease), lung diseases (chronic 
obstructive pulmonary disease, interstitial 
lung disease, sleep-disordered breathing, 
etc), systemic disorders, tumoral obstruction, 
connective tissue diseases and many others. 
Differential diagnosis is difficult.
In 1988 the patient noticed increased 
blood pressure (BP) up to 160/100 mm Hg 
for the first time. His general condition was 
satisfactory, and therefore the man didn’t 
seek any medical advice. Beginning in 2000 
he began to experience undue dyspnea, 
chest pain and fatigue during ordinary 
physical activity. At this point, he started to 
take antihypertensive drugs episodically, 
only during significant increases of BP. In 
2009 he suffered from myocardial infarction 
and was treated properly at a specialized 
regional center. Since the beginning of 2011 
the patient has been experiencing significant 
deterioration of his general condition: 
marked limitation of physical activity due to 
progressive dyspnea, fatigue, angina as well 
as episodes of tachycardia, and unstable 
BP. The patient is comfortable at rest, 
but sometimes has paroxysmal nocturnal 
dyspnea. Due to the severity of his condition, 
the patient was admitted to a local hospital 
with the diagnosis of coronary artery disease 
and arterial hypertension; however, there 
was no improvement as a result of treatment. 
In the beginning of 2012 the patient had a 
few episodes near syncope in addition to the 
previously mentioned complaints. He was 
hospitalized in a specialized regional center 
for additional diagnostic procedures and 
amendments of treatment.
As we know, the most common known 
causes for dyspnea are left side heart disease 
and lung diseases. At a first glance, the patient’s 
medical history suggests a diagnosis of left 
side heart failure due to ischemic heart disease 
and arterial hypertension (especially when 
taking into consideration myocardial infarction
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in 2009). However, the first manifestation 
of undue dyspnea refers to 2000, when the 
patient was quite young and didn’t have any 
symptoms other than rare moderate elevations 
of blood pressure. Besides, the ineffectiveness 
of in-hospital treatment for coronary artery 
disease in 2011 is a sufficient reason to re­
check the patient’s physical status.
The physical examination revealed left 
parasternal lift, an accentuated pulmonary 
component of second heart sound, a 
pansystolic murmur of tricuspid regurgitation, 
a diastolic murmur of pulmonary insufficiency, 
and a right ventricle third sound. His blood 
pressure was 120/80 mm Hg, and his 
heartbeat rate was 102 beats per minute. 
The patient’s lung sounds were normal, 
and his respiratory rate was 20 breaths per 
minute. Hepatomegaly was found, with no 
signs of ascites. A slight oedema of ankles 
and legs was revealed. His extremities were 
cool, especially wrists. His skin and mucosa 
were normal color. His BMI was 26,2 kg/m2.
According to the physical examination 
the patient has typical signs of pulmonary 
hypertension (PH), including signs of right 
ventricle overload, relative insufficiency of the 
tricuspid valve and increased blood pressure 
in the pulmonary artery. There is slight 
tachycardia and breathlessness. Hepatic 
congestion suggests further examinations to 
check the condition of his kidneys. Normal 
lung sounds assume the absence of chronic 
obstructive pulmonary disease, however 
further examinations should be performed to 
confirm this statement.
An electrocardiogram upon admission 
showed sinus rhythm, a heart rate of 96 beats 
per minute, right bundle-branch block, left 
posterior hemiblock, right venrticle hypertrophy 
and strain, and right atrial dilatation. The 
findings of the chest radiograph included 
central pulmonary arterial dilatation in contrast 
to the ‘pruning’ of the peripheral blood vessels, 
an enlarged right atrium and right ventricle. 
Transthoracic echocardiography confirmed 
the presence of marked dilatation of the right
heartchambers(end-systolic dimensionof right 
atrium 78 mm, lateromedial measurement; 
end-diastolic dimension of right ventricle 55 
mm, short axis parasternal view) as well as 
dilation of pulmonary artery trunk (40 mm). 
The systolic pulmonary artery pressure was 
101 mm Hg. There was fourth grade tricuspid 
regurgitation, and the gradient of regurgitation 
was 86 mmHg. Concerning the left heart 
chambers, a moderate enlargement of the 
left atrium (end-systolic dimension 56 mm, 
anteroposterior measurement), and normal 
sizes of the left ventricle were revealed; the 
ejection fraction was 66% and systolic output 
was 52 ml. The thickness of the interventricular 
septum was 18 mm. Hypokinetic motion of 
the posterobasal segment of the left ventricle 
was detected. There were no signs of systolic 
dysfunction. No remarkable changes of the 
mitral and aortic valves were found, and there 
were no signs of pericardial effusion.
The results of the coronarography show 
initial signs of atherosclerosis in both the left 
and right coronary arteries without significant 
derangements of haemodynamics. As 
confirmed by clinical findings, the patient has 
pronounced PH, complicated by right heart 
dilatation and right bundle-branch block. A few 
factors favoring a diagnosis of left ventricular 
diastolic dysfunction in the presence of PH 
can be found in this patient: hypertension, 
coronary artery disease, left atrial enlargement, 
and left ventricle hypertrophy (mainly the 
interventricular septum). However, the ejection 
fraction and systolic output are normal. 
Coronary arteries are almost intact. The PH 
seems to be out of proportion to the severity of 
left side heart disease in this particular patient. 
The other causes for PH, starting with lung 
diseases, should be looked for. As chest X-ray 
didn’t show any remarkable changes in the 
lungs, other noninvasive methods should be 
applied to assess lung structure and function.
Pulmonary function tests showed 
moderate reduction of FEV and FVC1. High- 
resolution computed tomography showed 
pronounced dilatation of the pulmonary artery
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trunk as well as main, lobar and segmental 
arteries, and tortuosity of the arteries (Figure 
1). The structure of the lungs and airways 
was normal; no signs of interstitial lung 
disease and emphysema were found. No 
signs of pulmonary embolism were detected.
The mild to moderate reduction of lung 
volume is typical for PH. It can also be 
seen in patients with chronic obstructive 
pulmonary disease, asthma, and other 
pulmonary diseases with mixed restrictive 
and obstructive patterns. As the patient didn’t 
have symptoms, signs or history of chronic 
lung diseases and no pathognomonic findings 
were revealed by additional assessment, 
the diagnosis of lung disease as a possible 
cause for PH was rejected.
Laboratory studies revealed a red blood 
cell count of 5.31012 per cubic liter (normal 
range, 4.0 to 5.1), hemoglobin 168 grams per 
liter (normal range, 130 to 160), hematocrit 
50.1%, and the erythrocyte sedimentation 
rate 29 mm per hour. Serum chemical profiles 
were notable for a blood urea level of 11.6 
mmol per liter (normal range, 3.3 to 6.6), and 
serum uric acid 428 mmol per liter (normal 
range, 208 to 420).
It is not surprising to observe a secondary 
erythrocytosis in patients with pronounced PH. 
A compensatory mechanism of increased red 
cell production is being launched by hypoxia 
in case of heart failure. Increased levels of 
blood urea and uric acid in the presence of 
unremarkable urine analysis suggest the 
presence of kidney congestion as the aftermath 
of congestive heart failure. Serum uric acid 
is also a marker of an impaired oxidative 
metabolism in the ischaemic peripheral tissue. 
High uric acid levels are known to relate to 
poor survival in patients with PH.
We performed a ventilation/perfusion lung 
scan in order to look for segmental perfusion 
defects as markers of less common diseases 
capable of provoking PH development.
The normal results of this scan helped us 
to exclude chronic thromboembolic pulmonary 
hypertension, pulmonary veno-occlusive disease,
and pulmonary capillary haemangiomatosis as 
possible causes for the PH.
Next, we considered the possibility of 
other uncommon causes of PH, starting 
with pulmonary artery hypertension, and a 
decision to perform right heart catheterization 
(RHC) was made.
The data obtained by the RHC included: 
systolic pulmonary artery pressure = 92 mm 
Hg, diastolic pulmonary artery pressure = 35 
mm Hg, mean pulmonary artery pressure 
(mPAP) = 52 mmHg, pulmonary wedge 
pressure (PWP) = 13 mm Hg, right atrial 
pressure = 18 mm, and cardiac output =
5.2 liters per minute. Pulmonary vascular 
resistance = 4.1 Wood Units. A vasoreactivity 
test with adenosine revealed a drop in mPAP 
of 16 mm Hg to the level of 36 mm Hg.
According to the findings of the RHC, the 
patient has pre-capillary PH. This statement 
fully denies the probability of PH as the result of 
left side heart disease. The good news is that 
the patient is a positive acute responder due to 
the results of the vasoreactivity test, so he may 
benefit from long-term therapy with calcium 
channel blockers (CCBs). A positive test is 
more often observed in patients with pulmonary 
artery hypertension (PAH): idiopathic or 
anorexigen associated. Nevertheless, other 
rare reasons for PAH should be considered.
When looking at connective tissue 
disease as a possible cause of PAH we were 
mainly concerned with systemic sclerosis, 
as it is the most common systemic disease 
PAH is associated with. As the patient was 
complaining of cold wrists, especially when 
exposed to a cold environment, and physical 
examination also revealed that they were pale 
and cold as a result of palpation, we suspected 
the presence of Raynaud’s phenomenon, 
which can be one of the symptoms of systemic 
sclerosis.
An antinuclear antibody test and an anti­
centromere antibody test were both negative. 
A nailfold capillaroscopy test was normal. 
Thermography with cold challenge showed a 
slight lowering of all indexes.
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Limited cutaneous systemic sclerosis 
(LCSS) may have slow onset and symptoms 
may be relatively unnoticed until internal 
complications occur. An anti-centromere 
antibody test seen almost only in patients with 
LCSS was essential for our patient, because 
it is associated with increased risk of PH. As 
the patient didn’t have any other clinical signs 
of systemic sclerosis, autoantibody tests were 
negative, and the nailfold capillaroscopy test 
was normal, we diagnosed primary Raynaud’s 
phenomenon. However, the origin of PAH still 
needed to be specified.
The patient reported no history suggestive 
of HIV or hepatitis. The history was supported by 
the negative results of serological testing. There 
were no physical signs or echocardiographic 
confirmation of congenital heart disease. 
History, physical examination and laboratory 
data revealed no signs of chronic hemolysis 
and shistosomiasis. Thyroid function test 
showed normal levels of thyroid hormones.
History of the patient’s exposure to 
drugs and toxins known to induce PAH 
was carefully collected. The patient had 
never take anorexigens, selective serotonin 
reuptake inhibitors, phenylpropanolamine, 
cocaine, pergolide or amphetamines.
As the result of our investigation, the 
differential diagnosis had narrowed to two 
possible causes for PAH: idiopathic or 
heritable PAH. The patient reported no family 
history of PAH. Therefore, the only remaining 
diagnosis in this case was idiopathic PAH.
IPAH remains a chronic disease without 
a cure. However, modern drug therapy leads 
to a significant improvement in patients’ 
symptoms and a slower rate of clinical 
deterioration [8, 9]. The management of 
IPAH in patients with comorbid coronary 
artery disease (CAD) is even more difficult. 
We followed the guidelines of the European 
Society of Cardiology and American Heart 
Association concerning the treatment of PH 
in our case patient [10, 11, 12].
As we know, only approximately 10% of 
patients with IPAH can be defined as positive 
acute responders by the results of RHC. Such 
patients are most likely to show a sustained 
response to long-term treatment with high 
doses of CCBs and they are the only patients 
that can safely be treated with this type of 
therapy [13]. Our patient was lucky to be one 
of them. The presence of relative tachycardia 
(100-110 beats per minute) favored the 
prescription of diltiazem (480 mg daily) for 
our patient. The heartbeat rate reduced to 90 
beats per minute after 1 week of treatment 
and didn’t show further dynamics. Adding 7.5 
mg of ivabradine twice daily decreased the 
heart rate to 68-74 beats per minute. Also, a 
modern targeted IPAH treatment was started: 
2.5 mcg of iloprost inhaled 6 times daily. In few 
days jaw pain developed as a side effect, but it 
didn’t require the termination of therapy. Other 
components of therapy were: 2,5 mg of warfarin 
once daily under the control of the international 
normalized ratio to prevent thrombotic events, 
and 12,5 mg of captopril three times daily to 
enhance blood pressure control. The follow- 
up done in 3 months showed an increase in 
exercise capacity according to a 6-minute 
walking test (300m in comparison to 120m at 
the beginning of therapy) and improvement 
in clinical symptoms. The B-type natriuretic 
peptide level was still moderately elevated, but 
lower than at the beginning of therapy. As the 
result of treatment the severity of pulmonary 
hypertension in our patient changed from the 
III to the II functional class according to WHO 
(1998) [14].
Conclusion. The present case underscores 
the need to consider a broad differential 
diagnosisformarkeddyspneainmaturepatients, 
especially when the intensity of dyspnea is 
out of proportion to the severity of underlying 
heart or lung diseases, or when symptoms 
fail to subside as expected in response to 
conventional therapy. Early diagnosis of IPAH 
is vitally important for initiating modern therapy 
in order to improve the quality and duration
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of life in such patients. As a result of the 
treatment, the significant clinical improvement 
was achieved in the patient, including reduced 
severity of symptoms, enhanced tolerance to 
physical exercise according to the 6-minute 
walk test, reduced functional class of heart 
failure and improved prognosis.
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Figure 1. High-resolution computed tomography showing 
pronounced dilatation o f the pulmonary artery trunk as well as main, 
lobar and segmental arteries, and tortuosity o f the arteries
